What is it about?
High quality comparative–effectiveness research has standardized surgery, radiotherapy and systemic chemotherapy. But there is still controversy on the selection of the best chemotherapeutic regimen and tailored targeted therapy.
Featured Image
Why is it important?
Because this is a summury about the latest results and the new changes in biomedical research that include applying highthroughput (HT) sequencing and array technologies to reach robust biomarkers and more effective drug combinations.
Perspectives
Three main research directions are now being shaped towards overcoming resistance to cetuximab or panitumumab. A combined inhibition of EGFR and MEK pathway, Wnt pathway inhibition and application of HT technologies for an integrated genome analysis of tumor samples from patients with CRC.
Dr Demosthenes E. Ziogas
Peripheral General Hospital of Ioannina - Xatzikosta
Read the Original
This page is a summary of: Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends, Expert Review of Gastroenterology & Hepatology, January 2013, Taylor & Francis,
DOI: 10.1586/egh.12.60.
You can read the full text:
Contributors
The following have contributed to this page
